[Today's headlines]
2026 edition of the National Basic Medical Insurance Drug Catalogue released, adding 107 new drugs
The 2026 edition of the National Medical Insurance Drug Catalogue was released on November 14, 2026. 107 new drugs were added, of which 51 were Class 1 innovative drugs, another record high.
The new catalogue will be officially implemented on January 1, 2027. This time's highlights:
1. CAR-T is included in basic medical insurance for the first time: Pharmaceutical Junuo's Rickie Orense injection became the first CAR-T product to enter the national medical insurance catalogue. The original price was over one million yuan, and patients' out-of-pocket expenses are expected to drop to less than 100,000 yuan after reimbursement.
2. The inclusion of non-factorial drugs for hemophilia: fentusilam sodium, emicalizumab, etc. filled the gaps in the catalog.
3. Domestic innovative drugs have outstanding performance: Cinda Biotech's Mashidu Peptide (the first domestically produced dual-target weight loss and hypoglycemic drug), Bailey Tianheng Yizekang (included in the first year of marketing), and Fuhong Hanlin Hans have all been included in the products.
4. Increase in the maximum payment limit for ophthalmic medication: The medical insurance payment amount for the two anti-VEGF ophthalmic drugs was adjusted from “cumulative maximum of 9 per eye” to “14 sticks”, the first increase in 9 years.
5. Drugs for assisted reproduction were included for the first time: injecting human follicle-stimulating hormone α luteinizing hormone α entered the catalogue.
This year, the commercial health insurance innovative drug catalogue continued to be adjusted simultaneously, adding 12 new drugs (including the world's first CAR-T for solid tumors and China's first hemophilia gene therapy drug), bringing the total to 28. At the same time, a bridging mechanism between the commercial insurance catalogue and the basic medical insurance catalogue has been established. Two types of the 2025 commercial insurance catalogue have already been transferred to basic medical insurance this year.
[General outlook]
The NASDAQ rose 2.27% last week, and Nvidia fell 13% to the biggest weekly decline since April 2025
Overnight, the Dow Jones Industrial Average rose 50.46 points from the previous trading day, or 0.1%, to close at 52347.55 points; the S&P 500 stock index fell 30.73 points to close at 7561.67 points, or 0.4%; and the Nasdaq Composite Index fell 229.82 points to close at 25136.27 points, or 0.91%. The Dow rose 2.07% last week, the NASDAQ surged 2.27% last week, and the S&P 500 surged 2.51% last week.
The US stock “Big Seven Tech” had mixed ups and downs. Meta Platforms rose 2.90%, Apple rose 0.39%, and the stock price reached a record high of closing; Nvidia fell more than 2%, and its stock price fell by a cumulative total of 13% last week, the biggest weekly decline since April 2025. It also fell for the sixth consecutive week, setting the longest continuous decline since 2012. Last week, the market value evaporated by more than 573 billion US dollars. Chip stocks fell. The Philadelphia Semiconductor Index closed down 3.43%, AMD fell more than 8%, SanDisk fell more than 5%, Western Digital fell 5%, Broadcom and ARM fell more than 4%, and Ram Research and Seagate Technology fell more than 3%.
The Nasdaq China Golden Dragon Index closed up 0.84%, with popular Chinese securities having mixed ups and downs. The Hang Seng Index ADR rose. On a proportional basis, it closed at 23729.90 points, up 92.30 points, or 0.39%, from the Hong Kong closing price.
WTI crude oil futures on the New York Mercantile Exchange rose 0.37 US dollars during the month to 89.11 US dollars per barrel, an increase of 0.42%. COMEX gold futures fell 5.30 US dollars in the same month, or 0.14%, to 3880.0 US dollars/ounce.
[Hot Topics Preview]
After inflation exceeded expectations, the Federal Reserve Collins stated: Further interest rate hikes are needed soon
Boston Federal Reserve Chairman Susan Collins (Susan Collins) said that as inflationary pressure spreads to more sectors, the Fed will “soon” need to raise interest rates further. However, she has yet to make a clear statement on the extent and pace of interest rate hikes, nor has she directly responded whether she supports the December rate hike of 50 basis points.
Chicago Federal Reserve Chairman Goulsby said on Friday that the latest inflation data is worrying, and the Federal Reserve may still need to take further action to contain rising prices and re-establish market confidence in the central bank's ability to control inflation. In an interview on the same day, Goulsby said, “I think the Federal Reserve clearly still has a lot of work to do before it can continue to rebuild its credibility.”
Foreign exchange reserve ratio of financial institutions increased to 6%
On November 15, the People's Bank of China officially implemented an increase in the foreign exchange reserve ratio of financial institutions. The foreign exchange reserve ratio was raised from the current 4% to 6%. This increase will help to balance supply and demand in the foreign exchange market and break the self-realization of expectations of RMB appreciation.
Cathay Pacific Haitong Asset Management clarifies false information spread online: private equity funds have never been used as counterparties
Recently, rumors have been circulating on the Internet about “an agency entrusting investment management to a company, carrying out an agreed repurchase with a private equity fund, and a repurchase default”. In response, Cathay Pacific Haitong Asset Management issued an announcement on November 14 clarifying that the content of the webcast had nothing to do with Shanghai Cathay Pacific Haitong Securities Asset Management Co., Ltd., and that the online transmission business was not carried out by Cathay Pacific Haitong Asset Management. Cathay Pacific Haitong Asset Management has long prohibited any form of cash or repurchase business with private equity funds, and has never traded with private equity funds as counterparties. Cathay Pacific Haitong Asset Management adheres to independent investment decisions and execution, and has established strict entry, approval and risk management and control mechanisms. There is no such online transmission business situation.
Pharmaceutical Juno-B (02126) plans to discount about 2.97% and issue a total of about 61.185,500 subscription shares to raise HK$160 million
Yao Ming Juno-B (02126) announced that on November 15, 2026, the company entered into a subscription agreement with China Hongqiao Holdings Limited or its designated entity and Novo Vista Limited Partnership to issue a total of approximately 61.185,500 subscription shares, HK$2.615 per share, at a discount of approximately 2.97% from the closing price of HK$2,695 per share reported by the Stock Exchange on the last trading day. The total subscription amount was HK$160 million.
Bank of China Gold Rental (01606) plans to purchase information technology computer equipment for 981 million yuan
Bank of China Gold Rental (01606) announced that the company, as the buyer and seller (Guangdong Shuhuan Zhilian Technology Co., Ltd.), signed a purchase agreement for this product on November 13, 2026. According to this, the seller agreed to sell to the buyer and the buyer agreed to purchase the subject of this procurement, at a total cost of approximately RMB 981 million. The subject of this procurement is information technology computer equipment.
China's Bolton (03318) subsidiary injects 160 million yuan into Shandong Ganghong Biotechnology to acquire 49% of the shares
Upon completion, Shenzhen Bolton will hold 49% of the target company's expanded registered capital. Therefore, the target company will be recorded as an associated company of the Company, and its financial results will not be incorporated into the Group's comprehensive financial statements.
Xinhua Wenxuan (00811) acquires 100% of the shares of Sichuan Minzu Publishing Co., Ltd.
The company received a notice from Sichuan Xinhua Publishing and Distribution Group, and the transaction was approved by the higher state-owned assets supervisory authority.
China Education Holdings (00839) expects annual net profit attributable to shareholders of about 630 million yuan to 770 million yuan
The above expected results take into account anticipated non-cash impairment losses (after deducting deferred taxes) of approximately RMB 1,060 million to RMB 1,140 billion, involving certain non-current assets located in two cash-generating units located in Henan and Sichuan provinces in China, which mainly reflect a reduction in expected future cash flows due to changes in the market environment and operating plans.
Zhaoke Ophthalmology-B (06622): Self-developed innovative drug Jingyouling® (cyclosporine eye gel) obtained marketing approval from the China Drug Administration
The indication is to promote tear secretion in patients with dry eyes. It is suitable for patients with reduced tear production due to dry eyes to improve their ocular signs.
Hanson Pharmaceuticals (03692): Ametinib marketing approval received positive opinions from the European Medicines Agency's Human Medicines Committee
Hanson Pharmaceuticals (03692) announced that on November 12, 2026, the European Medicines Agency (EMA) Committee on Medicines for Human Use (CHMP) adopted a positive opinion recommending that ametinib be granted marketing approval to treat non-small cell lung cancer.
TCL Electronics (01070) had strong performance growth in the first three quarters, adjusted net profit of HK$2,243 billion, up 54.5% year-on-year
In the first three quarters of 2026, the Group's Internet business revenue increased by 28.2% year-on-year to HK$2,695 billion. Among them, the expansion of the higher-margin international Internet business continued to accelerate, and its revenue share of Internet business revenue increased 17.0 percentage points year over year, driving the overall gross margin of the Internet business to increase 4.6 percentage points to 60.9% year on year, continuing to contribute high-quality profits.
[Individual stock prices are clear]
Yingpai Pharmaceutical-B (07630): Senapali's EU listing application is expected to be approved this month
Yingpai Pharmaceutical announced that the board of directors decided to use no more than HK$100 million to buy back H shares in the open market. All required capital comes from the company's own funds. Furthermore, depending on market conditions, the company may further repurchase H shares within the scope of the repurchase authorization granted by the shareholders' meeting.
Notably, senapalil received a positive opinion from the European Medicines Agency's Committee on Medicines for Human Use (CHMP) in September. Goldman Sachs said that the statement given by the management of Yingpai Pharmaceuticals on GS Asia Healthcare Enterprise Day is that Senapali's EU listing application is expected to be approved this month, based on receiving positive comments from the CHMP in September.